TABLE. Selected characteristics of cases of SARS-CoV-2 infection in residents aged ≥18 years (N = 422,966), by vaccination status — Los Angeles County, California, November 7, 2021–January 8, 2022*,†.
| Characteristic | Vaccination status, no. (column %) |
||
|---|---|---|---|
| Unvaccinated | Fully vaccinated without booster | Fully vaccinated with booster | |
|
Total no. of cases (row %)
|
141,928 (33.6)
|
224,853 (53.2)
|
56,185 (13.3)
|
|
Median age, yrs (IQR)
|
35 (27–48) |
36 (27–49) |
46 (33–59) |
| 18–29 |
48,940 (34.5) |
74,352 (33.1) |
9,523 (16.9) |
| 30–49 |
61,380 (43.2) |
97,771 (43.5) |
22,649 (40.3) |
| 50–64 |
22,338 (15.7) |
40,680 (18.1) |
14,580 (25.9) |
| 65–79 |
7,253 (5.1) |
9,796 (4.4) |
7,960 (14.2) |
| ≥80 |
2,017 (1.4) |
2,254 (1.0) |
1,473 (2.6) |
|
Sex
| |||
| Women |
69,382 (48.9) |
123,927 (55.1) |
30,864 (54.9) |
| Men |
66,163 (46.6) |
94,258 (41.9) |
23,713 (42.2) |
| Other or unknown |
6,383 (4.5) |
6,668 (3) |
1,608 (2.8) |
|
Race/Ethnicity§
| |||
| American Indian or Alaska Native |
342 (0.2) |
426 (0.1) |
104 (0.2) |
| Asian |
7,451 (5.2) |
18,043 (8.0) |
8,341 (14.8) |
| Black or African American |
12,319 (8.7) |
13,359 (5.9) |
2,632 (4.6) |
| Hispanic or Latino |
42,973 (30.3) |
79,198 (35.2) |
14,023 (25.0) |
| Multiple race |
494 (0.3) |
968 (0.4) |
210 (0.3) |
| Native Hawaiian or Other Pacific Islander |
1,429 (1.0) |
1,740 (0.7) |
608 (1.0) |
| Other |
18,720 (13.2) |
32,552 (14.5) |
6,808 (12.1) |
| White |
20,529 (14.5) |
34,108 (15.2) |
12,504 (22.3) |
| Missing |
37,671 (26.5) |
44,459 (19.8) |
10,955 (19.5) |
|
Previously documented SARS-CoV-2 infection
|
12,360 (8.7) |
22,153 (9.9) |
3,246 (5.8) |
|
Hospitalized
|
3,989 (2.8) |
2,295 (1.0) |
413 (0.7) |
|
Admitted to an intensive care unit
|
641 (0.5) |
276 (0.12) |
47 (0.08) |
|
Required mechanical ventilation
|
256 (0.2) |
116 (0.05) |
15 (0.03) |
|
Died
|
485 (0.3) |
172 (0.08) |
40 (0.07) |
|
Vaccine manufacturer¶
| |||
| Johnson & Johnson |
— |
18,543 (8.2) |
4,869 (8.7) |
| Moderna |
— |
82,435 (36.7) |
19,742 (35.1) |
| Pfizer-BioNTech |
— |
123,875 (55.1) |
31,574 (56.2) |
|
Median interval between final vaccine dose and infection, days (IQR)**
|
— |
241 (200–271) |
49 (31–70) |
|
Sequencing result available
|
7,087 (5.0) |
9,663 (4.3) |
1,296 (2.3) |
|
Sequencing result
| |||
| Delta |
3,817 (53.9) |
3,471 (35.9) |
128 (9.9) |
| Omicron |
3,248 (45.8) |
6,180 (64.0) |
1,164 (89.8) |
| Other | 22 (0.3) | 12 (0.1) | 4 (0.3) |
* Partially vaccinated persons were excluded from this analysis.
† A Pearson’s chi-square test was conducted for categorical variables and Kruskal-Wallis test for medians; p<0.001.
§ Race and ethnicity were defined as mutually exclusive categories. Hispanic or Latino includes all persons with ethnicity reported as “Hispanic or Latino” regardless of reported race. “Other” Race/Ethnicity includes persons of multiple races, and persons for whom reported race was “Other.” Missing values were included in statistical testing.
¶ The primary vaccine series was used to categorize persons by vaccine manufacturer type regardless of which vaccine manufacturer was received for the booster dose.
** Infection date refers to the earliest of either the date of symptom onset, diagnosis, death, report received, or specimen collection.